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Background: Low-grade inflammation plays significant role in the development of diabetes mellitus type 2 (DM2)
and impaired glucose tolerance (IGT), but immune regulatory mechanisms involved in these processes are studied
incompletely. The purpose of the present study was to characterize the subsets of T-helper-1 (Th1), Th17 and
T-regulatory lymphocytes (Treg) in hypertensive patients with DM2 or IGT according to the clinical variant of the disease.
Methods: Hypertensive patients with DM2 (n = 20) and IGT (n = 7) were recruited in the study. Hypertensive patients
without carbohydrate disturbances (n = 7) and healthy volunteers (n = 12) constituted comparison groups. All patients
underwent thorough clinical examination. Th1-, Th17- and Th1/Th17-lymphocytes were assessed in peripheral blood
mononuclear cells (PBMC) according to intracellular production of interferon (IFN)-γ and interleukin (IL)-17. Expression
of receptor to IL-23 (IL-23R) by PBMC was evaluated. Treg-lymphocytes were detected in PBMC by expression of
transcription factor FoxP3. Cells were analyzed using flow cytometry.
Results: We found that ratio Treg/Th17 was lower and numbers of IL-23R-positive cells were higher in hypertensive
patients with IGT. Patients with DM2 were characterized by elevated numbers of Th17-lymphocytes in intact PBMC culture
and Th1-lymphocytes after PBMC activation, as well as decreased ratios Treg/Th17 and Treg/Th1, and reduced numbers
of Tregs that were inversely related to visceral adiposity index. In hypertensive patients with DM2 glomerular filtration
rate was related to numbers of intact Th17- and IL-23R+ cells and FoxP3+ Treg-lymphocytes, while values of Treg/Th1
ratio were interconnected with visceral adiposity index and concentrations of total cholesterol and LDL-cholesterol.
Conclusions: Our study underlines the importance of immune imbalance in the development of carbohydrate
metabolism perturbations in hypertensive patients even at the stage of impaired glucose tolerance. Further
prospective research is needed to elaborate the possible strategy of the risk evaluation for hypertensive DM2 and
IGT patients according to their current inflammatory status and propose therapeutic approaches for its correction.
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The presence of diabetes mellitus type 2 (DM2) in pa-
tients with arterial hypertension (AH) significantly amp-
lifies development of microvascular and macrovascular
complications, and results in increased mortality [1, 2].
DM2 is an independent risk factor for the development
of cardiovascular events [3, 4]. The risk of infarction and
coronary heart disease death in DM2 patients is as high
as in patients with the history of previous myocardial
infarction [5, 6]. The widespread of DM2, observed now-
adays, may partially be explained by the fact that people
with impaired glucose tolerance (IGT, may also be re-
ferred as “prediabetes”) remain undiagnosed [3]. During
IGT the regulation of carbohydrate metabolism is
already disturbed, but the fasting glucose and glycated
hemoglobin (HbA1c) levels are lower than those
observed during DM, or may even remain in the range
of normal values [7]. IGT precedes the development of
DM2 in 25 % of cases, and patients with IGT also have
high risk of vascular complications [3, 7].
It had been shown that chronic low-grade inflamma-
tion plays significant role in the development of DM2
and insulin resistance, but its mechanisms are not yet
thoroughly explored [8–10]. There is no general consen-
sus if inflammation during DM2 has pathogenic role or
may fulfill the protective function, while its agents may
be regarded as biomarkers of the disease [11, 12].
Macrophages are considered to be the main effector
cells during metabolic inflammation during DM2 and
its complications [13]. However it had been shown that
T-lymphocytes may also be found in the adipose tissue,
kidney parenchyma and other target tissues during DM2
[14, 15]. These findings confirmed that cells of adaptive
immunity may act as important regulators during the
development of DM2-associated inflammation.
Imbalance between inflammatory T-helper subpopula-
tions (Th17 and Th1) and immunosuppressive regulatory
T-lymphocytes (Tregs) had proven to be of great signifi-
cance in many diseases accompanied by inflammation,
such as rheumatoid arthritis, systemic sclerosis, diabetes
mellitus type 1, acute coronary syndrome etc. [16–18].
Among the consequences of imbalance between proin-
flammatory T-helpers and Tregs one may list elevated
production of inflammatory cytokines, predisposition
to autoimmunity, increased autoantibody production
[19, 20]. All these factors are favorable for the creation
of inflammatory milieu and may contribute to the
development and maintenance of insulin resistance
during DM2 [8–10].
Multiple experimental works specify association of in-
sulin resistance, obesity and increased numbers of Th17,
as well as Th1 lymphocytes, together with reduction of
FoxP3+ Tregs’ frequency in adipose tissue and spleen
[21, 22]. But we have encountered just a limited numberof studies exploring functioning of Th17 and Treg cells
in DM2 patients, where the clinical implications of
immune dysregulation were not sufficiently addressed
[23, 24]. It had been shown that functioning of Th17-
lymphocytes has its peculiarities in humans compared to
mice, that is why not all the data obtained in experi-
mental models of DM2 and AH can be extrapolated
into patients’ cohort [25]. To our knowledge no works
were undertaken to estimate the functional activity of
Th1/Th17/Treg-lymphocytes in patients with IGT.
The purpose of the present study was to characterize
the subsets of Th1, Th17 and Treg-lymphocytes in
hypertensive patients with DM2 or IGT, and to conduct
analysis of relationships between immune dysregulation
and clinical features of patients with DM2.
Methods
Patients
The study protocol was approved by the local Biomedical
Ethics Committee of RI Cardiology (protocol number 62
from 07.04.2010). All the patients gave the informed
consent to participate in the study. All the procedures
were performed in accordance with the Helsinki Declar-
ation, Good Clinical Practice (GCP) and Good Laboratory
Practice (GLP).
During the case–control study all the patients were
stratified into 3 groups: hypertensive patients with DM2,
hypertensive patients with IGT and hypertensive patients
without carbohydrate disturbances (constituted com-
parison group). Control group of healthy volunteers
was also recruited and constituted the fourth group.
Characteristics of patients and healthy volunteers are
represented in Table 1.
All patients recruited in the study received regular
antihypertensive therapy, including combination of
renin-angiotensin-aldosterone system blockers (83 %
AH patients; 65 % DM2 patients and 71 % IGT patients),
indapamide retard (67 % AH patients; 45 % DM2 pa-
tients and 57 % IGT patients), calcium channel blockers
(33 % AH patients; 40 % DM2 patients and 14 % IGT
patients), beta-blockers (17 % AH patients; 30 % DM2
patients and 30 % IGT patients). 10 recruited patients
(29 % of all patients) received low doses of statins (ator-
vastatin in the mean dose 15 mg and rosuvastatin in the
mean dose 7.5 mg). 70 % DM2 patients received oral
glucose-lowering medications, including biguanides and
sulphonylurea derivatives. Healthy volunteers did not
receive any medication at least 3 weeks prior to the re-
cruitment in the study.
Glomerular filtration rate (GFR) was calculated using
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation. All the patients and healthy vol-
unteers recruited in the study had preserved renal
function with GFR > 60 ml/min/1.73 m2.
Table 1 Characteristics of recruited patients and healthy volunteers, Me (Q1 – Q3)
Parameters Healthy volunteers Hypertensive patients Hypertensive diabetic patients Hypertensive patients with IGT
(n = 12) (n = 7) (n = 20) (n = 7)
Male/female, n 5/7 3/4 10/10 2/5
Age, years 42.0 (40.0–52.5) 51.0 (47.0–56.0)* 56.5 (50.0–62.0)* 58.0 (56.0–61.0)*
Systolic blood pressure, mm Hg 125.0 (118.0–133.5) 130.0 (120.0–140.0) 130.0 (117.0–142.0) 140.0 (140.0–154.0)
Diastolic blood pressure, mm Hg 80.0 (78.0–84.5) 90.0 (80.0–95.0) 80.0 (76.0–88.0)** 90.0 (90.0–94.0)#
Body mass index (BMI), kg/m2 24.1 (22.3–30.5) 33.3 (29.0–37.0) 32.4 (29.3–35.4) 31.0 (29.0–33.2)
Waist circumference, cm male 85.0 (85.0–89.0) 95.0 (88.0–100.0) 104.5 (102.0–106.0) 99.0 (98.0–100.0)
female 80.0 (74.0–82.0) 99.5 (90.0–109.0) 110.0 (107.0–116.0) 105.0 (100.0–110.0)
Visceral adiposity index 1.6 (0.8–3.0) 2.0 (1.9–2.5) 3.6 (2.3–4.8)* 2.4 (1.9–3.4)
DM2 duration, years n/a n/a 3.0 (1.0–10.5) n/a
AH duration, years n/a 9.0 (7.0–15.0) 9.0 (5.0–11.5) 5.0 (0.0–13.0)
Glomerular filtration rate (CKD-EPI),
ml/min/1.73 m2
97.5 (83.0–111.0) 93.0 (87.0–102.0) 87.0 (81.0–104.0) 105.0 (96.0–114.0)
Insulin, μIU/ml 8.5 (6.9–17.2) 17.4 (10.3–23.6) 16.0 (11.2–27.8)* 17.4 (9.6–21.6)*
C-peptide, ng/ml 1.8 (1.1–2.6) 3.0 (2.5–4.1)* 3.0 (2.3–3.7)* 2.2 (1.9–3.2)*
Fasting glucose, mmol/l 5.4 (4.9–6.5) 4.9 (4.7–5.6) 7.8 (6.8–9.3) ** 5.4 (5.1–5.7)#
HOMA 1.8 (1.0–6.9) 3.8 (2.6–5.0) 5.4 (3.7–9.4) 4.4 (2.2–5.4)
HbA1c, % 5.5 (4.9–5.7) 5.1 (4.9–5.5)* 8.3 (6.7–9.3) *, ** 6.0 (4.9–7.5)*
Total cholesterol, mmol/l 5.7 (4.5–6.8) 6.8 (5.9–7.2) 5.4 (4.7–6.4) 5.4 (5.3–5.6)
Triacylglycerol, mmol/l 1.1 (0.8–2.3) 2.1 (1.2–2.6) 2.3 (1.8–3.0)* 1.5 (1.4–2.1)
LDL cholesterol, mmol/l 3.7 (2.6–4.6) 4.7 (4.5–4.9) 3.2 (2.6–4.1) 3.4 (3.1–3.8)
HDL cholesterol, mmol/l 1.4 (1.2–1.6) 1.1 (0.8–1.2)* 1.1 (0.9–1.3)* 1.3 (1.0–1.4)*
LDL/HDL 2.7 (1.7–3.4) 4.6 (3.4–5.9)* 3.1 (2.3–4.2) 2.9 (2.2–3.5)
DM2 diabetes mellitus type 2, AH arterial hypertension, IGT impaired glucose tolerance, HOMA homeostatic model assessment for insulin resistance, LDL low
density lipoproteins, HDL high density lipoproteins, Me median, Q1 25
th percentile, Q3 75
th percentile
*p < 0.05 compared to healthy volunteers, **p < 0.05 compared to patients with AH, #p < 0.05 compared to patients with DM2; n/a – not applicable to the group
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the formula for male patients: VAI = (WC/(39.68 + (1.88 x
BMI))) x (TG/1.03) x (1.31/HDL); for female patients:
VAI = (WC/(36.58 + (1.89 x BMI))) x (TG/0.81) x (1.52/
HDL), where WC – waist circumference; BMI – body
mass index [26].
Fasting samples of peripheral blood were obtained into
4 ml heparinized tubes, 4 ml tubes with EDTA and in
10 ml tubes without anticoagulant.
Biochemical analyses
Insulin and C-peptide concentrations were evaluated in
serum by enzyme-linked immunosorbent assay (AccuBind,
USA; Diagnostic System Laboratories, USA). Serum con-
centration of glucose was measured by glucose oxidase
method using analyzer BIOSEN C-line Clinic (EKF diag-
nostic, Germany). Enzyme colorimetric method was used
to estimate serum concentration of total cholesterol, triac-
ylglycerol, high-density lipoprotein (HDL) cholesterol
(Diakon, Russia). Concentration of low-density lipoprotein
(LDL) cholesterol (using formula [LDL] = [Total choles-
terol] – [Triacylglycerol (TG)] – [HDL]) and LDL/HDLratio was calculated. Glycated hemoglobin (HbA1c)
content was measured by immunoturbidimetric method
(DiaSys, Germany).
Homeostatic model assessment for insulin resistance
(HOMA) was calculated according to equation:
HOMA = ([fasting glucose, mmol/l] × [fasting insulin,
μIU/ml]) /22,5.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinized blood by centrifuging on Histopaque
1077 (Sigma-Aldrich, USA).
Th1-lymphocytes and Th17-lymphocytes were identified
by intracellular production of interferon-gamma (IFN-γ)
and interleukin 17 (IL-17) respectively. For this purpose
PBMC were cultured on the RPMI 1640 medium supple-
mented with heat inactivated fetal bovine serum (10 %),
L-glutamine (1 %) and penicillin/streptomycin (1 %) at
37 °C, 5 % CO2 in the presence of GolgiPlug, containing
brefeldin A (BD Pharmingen, USA). Phorbol-12-miristate-
13-acetate (PMA) in the final concentration 50 ng/ml
(Sigma-Aldrich, USA) and ionomycin (1 μg/ml, Sigma-
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Intact unstimulated PBMC were run in parallel as a con-
trol sample and to evaluate spontaneous cytokine produc-
tion ex vivo, which was regarded as a sign of prior in vivo
stimulation [27]. In 6 h 100 μl of PBMC suspension were
stained with PE-Cy5-labeled anti-CD4 (Becton Dickinson,
USA) and APC-labeled anti-IL23R (R&D, USA), fixed,
treated with 1x permeabilizing buffer (BD Pharmingen,
USA), stained with PE-labeled anti-IL17A (R&D, USA)
and FITC-labeled IFN-γ (Becton Dickinson, USA). Stained
cells were stored in the fixing buffer (BD Pharmingen,
USA) and analyzed not later than 12 h after preparation of
the sample. Cells producing both IL-17 and IFN-γ were
referred as double-positive Th1/Th17-lymphocytes.
Numbers of IL-17+ and IFN-γ + cells were evaluated as
well as mean fluorescence intensity (MFI), which reflected
relative cytokine production at a single-cell level.
FoxP3+ Tregs were identified by the presence of intra-
cellular transcription factor FoxP3. To identify this cell
subpopulation PBMC were stained with FITC-labeled
anti-CD4 and APC-labeled anti-CD25 (Becton Dickinson,
USA), fixed and permeabilized with matching buffer set
(Becton Dickinson, USA), stained with PE-labeled anti-
FoxP3 antibodies (Becton Dickinson, USA) and stored in
the fixing buffer up to the final analysis not later than 12 h
after preparation.
Cells were analyzed on a FACSCalibur flow cytometer
using CellQuestPro software (BD Biosciences, USA).
Statistical analyses
Analyses were performed in Statistica 10 (StatSoft Inc.,
USA). The Mann-Witney U-test was used to estimate
the reliability of differences between groups. Spearman’s
rank correlation coefficient (r) was used to estimate stat-
istical dependence between variables. A value of p < 0.05
was considered statistically significant.
Results
Analysis of Th1, Th17 and Th1/Th17 lymphocytes
showed that patients with DM2 had elevated numbers of
Th17 in intact PBMC culture, elevated numbers of Th1
after stimulation of PBMC with PMA + ionomycin and
lowered numbers of Th1/Th17 double-positive lympho-
cytes compared to healthy volunteers (Fig. 1). Numbers
of Th1, Th17 and Th1/Th17 lymphocytes did not signifi-
cantly differ between patients groups (Fig. 1). Of note
that several patients with IGT were characterized by sig-
nificantly elevated frequency of Th17-lymphocytes after
PMA + ionomycin stimulation, which reached numbers
twice as high as in the group of patients with DM2 and
AH and healthy volunteers (Fig. 1a; one representative
result out of two). However the whole group of patients
with IGT was rather heterogeneous and relatively low
number of patients in the group did not allow performingany stratification. Due to this reason no statistically signifi-
cant differences was shown compared to patients with
DM2 and AH.
Hypertensive patients with DM2 had higher MFI of
IFN-γ in Th1-lymphocytes from intact and PMA+ iono-
mycin stimulated PBMC culture compared to healthy
volunteers (Table 2). Analysis of MFI for IL-17 and IFN-γ
in Th1/Th17 lymphocytes showed different kinds of cyto-
kine production in double positive cells depending on cir-
cumstances of cell cultivation and pathology involved.
Th1/Th17-cells of IGT patients were characterized by
lower MFI of IL-17 in intact CD4+ lymphocytes compared
to patients with AH (p = 0.018), with DM2 (p = 0.001) and
healthy volunteers (p = 0.008) (Table 2). MFI of IFN-γ in
Th1/Th17 lymphocytes after PMA+ ionomycin stimula-
tion in patients with IGT was lower compared to patients
with DM2 (p = 0.003; Table 2). Moreover, all the groups of
hypertensive patients had lower MFI of IFN-γ in intact
Th1/Th17-lymphocytes compared to healthy volunteers,
while MFI of IL-17 in PMA-activated Th17-lymphocytes
was lower in patients with AH and DM2 compared to
healthy volunteers (Table 2).
We have examined number of cells expressing receptor
to IL-23 (IL-23R+ cells). It turned out that patients with
IGT were characterized by the highest expression of IL-
23R compared to patients with AH and healthy volunteers
(Fig. 2). Number of IL-23R+ cells was also elevated in the
group of patients with DM2 compared to healthy volun-
teers (Fig. 2). IL-23 is known to play the crucial role in the
functional activity of Th17 [28].
Numbers of FoxP3+ T-regulatory lymphocytes in pa-
tients with DM2 were lower than in patients with AH and
healthy volunteers (Fig. 3). Correlation analysis showed
that numbers of FoxP3+ Tregs were negatively related to
VAI in patients with DM2 (R = −0.517; p = 0.034; Fig. 4).
We calculated ratios Treg/Th17 and Treg/Th1 for intact
and PMA+ ionomycin cell culture. We regarded this ratio
as the representation of the severity of imbalance in
immune dysregulation in patients: the lower it was – the
more pronounced immune imbalance was considered to
be. Our data showed that patients with DM2 had lower
ratios Treg/Th17 and Treg/Th1 both in intact and
PMA+ ionomycin activated PBMC culture compared to
healthy volunteers (Table 3). Patients with DM2 were also
characterized by the lower ratios Treg/Th17 and Treg/Th1
in intact PBMC culture and lower Treg/Th1 ratio after
PMA+ ionomycin stimulation compared to non-diabetic
AH patients (Table 3). Ratio Treg/Th17 in patients with
IGT was lower compared to patients with AH (p = 0.042)
while ratio Treg/Th1 after PMA-induced activation was
lower compared to healthy volunteers (Table 3). As for
non-diabetic patients with AH, the only difference be-
tween this group and group of healthy volunteers was de-









































































Fig. 1 T-helper subpopulations in patients with AH, DM2 and IGT. a Representative dot-plots showing numbers of Th1-, Th17-, Th1/Th17-lymphocytes
in healthy volunteer (first column) and groups of patients (second column – patient with arterial hypertension; third column – hypertensive
patient with DM2; fourth column – hypertensive patient with IGT). Cells were gated according to their expression of CD4. Only CD4+ cells are
shown. b Numbers of Th1-, Th17-, Th1/Th17-lymphocytes in healthy volunteers (n = 12) and patients with AH (n = 7), DM2 (n = 20), IGT (n = 7)
in intact PBMC culture (Media) and after stimulation (PMA + ionomycin). Data represent the mean and SEM; p-values represented above the
bars are calculated by Mann–Whitney U test. All other comparisons were statistically insignificant (p > 0.05)
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if immunoregulatory imbalance revealed in patients’
groups was associated with any clinical or biochemical
changes. Multiple correlations were observed in the
group of hypertensive patients with DM2. Glomerular
filtration rate was negatively related to numbers of
Th17-lymphocytes, IL-23R+ cells and FoxP3+ Treg-lymphocytes (Fig. 4). Decrease of Treg/Th1 ratio was
associated with elevation of visceral adiposity index,
while lowered ratio Treg/Th1 (after stimulation with
PMA + ionomycin) was accompanied by increase of
concentrations of total cholesterol and LDL-cholesterol
(Fig. 4). These correlations were absent in other groups
of patients and healthy volunteers.
Table 2 MFI of cytokines produced by Th1, Th17 and Th1/Th17-lymphocytes in patients with AH, DM2, IGT and healthy volunteers,









(n = 12) (n = 7) (n = 20) (n = 7)
MFI (IL-17) in Th17- lymphocytes (media) 87 (49–108) 81 (67–91) 94 (74–97) 74 (39–94)
MFI (IFN-γ) in Th1- lymphocytes (media) 27 (20–47) 52 (36–77) 50 (46–52)* 46 (37–53)
MFI (IL-17) in Th1/Th17- lymphocytes (media) 479 (368–511) 277 (255–336) 351 (280–434) 93 (63–237)*, **, #
MFI (IFN-γ) in Th1/Th17- lymphocytes (media) 375 (243–480) 349 (305–349)* 303 (166–381)* 143 (81–309)*
MFI (IL-17) in Th17- lymphocytes (PMA + ionomycin) 131 (117–163) 103 (98–109)* 109 (87–129)* 97 (83–114)
MFI (IFN-γ) in Th1- lymphocytes (PMA + ionomycin) 215 (63–400) 132 (129–184) 267 (187–318)** 115 (76–181)
MFI (IL-17) in Th1/Th17- lymphocytes (PMA + ionomycin) 277 (200–386) 163 (158–166) 93 (64–168)* 128 (48–175)
MFI (IFN-γ) in Th1/Th17- lymphocytes (PMA + ionomycin) 182 (118–197) 209 (205–218) 262 (220–505) 102 (76–198)#
Me median, Q1 – 25
th percentile, Q3 – 75
th percentile
*p < 0.05 compared to healthy volunteers, **p < 0.05 compared to patients with AH, #p < 0.05 compared to patients with DM2
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Our study revealed that perturbations of carbohydrate
metabolism are accompanied by distinguishable changes
in the immune-regulatory status of hypertensive patients.
The changes are observed already at the stage of IGT and
are still present in patients with DM2, even though











Fig. 2 The expression of receptors to IL-23. a Representative flow cytometr
PBMC after stimulation with PMA + ionomycin (right graph; PMA). Data for
and IGT are represented in each histogram. b Number of cells, positive fo
(n = 7) in intact PBMC culture (Media) and after stimulation (PMA + ionom
the bars are calculated by Mann–Whitney U test. All other comparisons wTo our knowledge no previous works evaluated T-
helper subpopulations in patients with IGT. Normally
these patients remain undiagnosed and untreated unless
they have another associated pathology. This made re-
cruitment of patients into this group rather a compli-
cated task, with the small number of IGT patients being
















y analysis of IL-23R expression in intact PBMC (left graph; media) and
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ycin). Data represent the mean and SEM; p-values represented above
























Fig. 3 FoxP3+ T-regulatory cells. a Representative dot-plots showing numbers of FoxP3+ T-regulatory cells in healthy volunteers and patients with
AH, DM2, IGT. Percentage indicates number of cells among all CD4 + −lymphocytes. b Numbers of FoxP3+ T-regulatory lymphocytes in healthy
volunteers (n = 12) and patients with AH (n = 7), DM2 (n = 20), IGT (n = 7). Data represent the mean and SEM; p-values represented above the bars
are calculated by Mann–Whitney U test. All other comparisons were statistically insignificant (p > 0.05). c Relationship between visceral adiposity
index (x-axis) and numbers of FoxP3+ T-regulatory lymphocytes (y-axis) in patients with DM2. The p-value indicated in (c) was calculated using
Spearman correlation; Spearman’s rank correlation coefficient (r) is indicated above p
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populations in this group, some patients with IGT
were characterized by pronounced activation of Th17-
lymphocytes. Also, we revealed elevated expression of
IL-23R, necessary for IL-17 production in all patients
with IGT. Probably, some additional factor is required
for T-helpers to differentiate into Th17-lineage in these
patients. We also revealed lowered ratio Treg/Th17 in
IGT patients, as an indicator of Th17 cells’ excessive
activation during IGT. Th17 cells are known to play the
leading role at the beginning of the development of
various diseases [29–31]. It had been shown that their
activity subsides through the progression of the disease
with Th1-lymphocytes taking over the leading position
in the development of inflammation [30, 31]. Further
studies are required to address the functioning of
Th17-lymphocytes in hypertensive patients with IGT.
Increased numbers of Th17-lymphocytes were observed
in patients with DM2 only in intact unstimulated PBMC
culture, but not after stimulation with PMA+ ionomycin.
Intensity of IL-17 production at a single cell level after
PMA stimulation was also lower in patients with DM2,
compared to healthy volunteers (Table 2). Most probably,
Th17-cells were already activated in vivo during DM2, and
exhibited functional exhaustion during additional stimu-
lation ex vivo. Exposure to chronic inflammation may di-
minish effector functions of T-lymphocytes, which mayimpair protection against infections and cause predis-
position to cancer, which is typical to diabetic patients
[32–34]. It had also been shown that patients with DM2
are characterized by lower numbers of Th17, specific to
infectious pathogens [35].
Our results point out that important role in pathogenesis
of inflammation during DM2 belongs to Th1-lymphocytes,
as we observed elevation of IFN-γ + cells’ percentage in
PMA+ ionomycin stimulation and MFI of IFN-γ in intact
and stimulated Th1 compared to control groups (Fig. 1;
Table 2). Number of works pointing out the role of Th1
lymphocytes in pathogenesis of insulin resistance and
DM2 is abundant [24, 36–38]. It was shown that IFN-γ
deficiency was associated with improved insulin sensiti-
vity and glucose homeostasis in experimental models
[38]. IFN-γ, produced by Th1 in obesity, participates in
the recruitment of proinflammatory M1-macrophages
and other inflammatory cells to adipose tissue with sub-
sequent induction of insulin resistance [37]. In many
experimental works Th1 and FoxP3+ Treg-lymphocytes
displayed antagonistic relationships: increase in Th1
numbers was associated with the decline of Treg fre-
quency and increase of insulin resistance [21, 38]. Our
study showed that decreased Treg/Th1 ratio in DM2
patients is associated with increase of visceral index of
adiposity, elevation of total cholesterol and LDL choles-


















Fig. 4 Relationships between clinical and immune parameters in patients with DM2. a Relationship between numbers of Th17-lymphocytes in
intact PBMC culture (x-axis) and glomerular filtration rate (y-axis); b relationship between numbers of IL-23R+ cells in intact PBMC culture (x-axis)
and glomerular filtration rate (y-axis); c relationship between numbers of FoxP3+ Treg-lymphocytes (x-axis) and glomerular filtration rate (y-axis);
d relationship between values of Treg/Th1 ratio in intact PBMC culture (x-axis) and visceral adiposity index (y-axis); e relationship between values
of Treg/Th1 ratio in PMA + ionomycin stimulated PBMC culture (x-axis) and concentration of total cholesterol (y-axis); f relationship between
values of Treg/Th1 ratio in PMA + ionomycin stimulated PBMC culture (x-axis) and concentration of LDL-cholesterol (y-axis). The p-value indicated
in all the graphs was calculated using Spearman correlation; Spearman’s rank correlation coefficient (r) is indicated above p
Table 3 Ratios between different subpopulations of T-lymphocytes in groups of patients, Me (Q1 – Q3)
Ratio Healthy volunteers Hypertensive patients Hypertensive diabetic patients Hypertensive patients with IGT
(n = 12) (n = 7) (n = 20) (n = 7)
Treg/Th17 (media) 59.13 (22.57–70.58) 49.08 (47.60–61.64) 20.55 (16.40–35.58)*, # 32.43 (10.17–46.54)#
Treg/Th1 (media) 59.14 (22.57–70.58) 84.14 (66.38–87.00) 31.56 (19.27–37.63) *, # 48.25 (13.90–86.43)
Treg/Th17 (PMA + ionomycin) 15.33 (12.59–16.80) 8.99 (7.10–9.20)* 7.05 (4.46–12.57)* 6.08 (4.54–27.50)
Treg/Th1 (PMA + ionomycin) 0.57 (0.51–0.60) 0.46 (0.37–0.47) 0.19 (0.14–0.29)*, # 0.25 (0.12–0.39)*
Me median, Q1 25
th percentile, Q3 75
th percentile
*p < 0.05 compared to healthy volunteers, #p < 0.05 compared to patients with AH
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lymphocytes in intact PBMC culture tended to be
lower in all groups of patients compared to healthy
volunteers and significantly lower in the group of pa-
tients with DM2 (Fig. 1). These cells are involved in
the development of tissue inflammation, are less sus-
ceptible to suppression by FoxP3+ Treg-lymphocytes
and are present in rather high numbers in healthy
adult persons [39, 40]. Both Th17- and Th1/Th17-
lymphocytes are characterized by high plasticity and
can be polarized into different T-helper subpopula-
tions if proper micro-environmental milieu is created
[25, 39, 41]. Being placed in polarizing conditions fa-
vorable for the differentiation of Th1, double-positive
lymphocytes may cease the production of IL-17 and
start producing solely IFN-γ [42]. Possible explanation
for decreased numbers of double-positive Th1/Th17-
lymphocytes in hypertensive DM2 patients observed
in our study is transformation of pool of cells, consti-
tuting this subpopulation, into Th1-cells, which were
found in elevated numbers, as we discussed above. We
have also observed lowered MFI for IL-17 in Th1/
Th17-lymphocytes from DM2 patients, while MFI for
IFN-γ tended to be higher than in AH patients and
healthy volunteers, and was significantly higher than
in IGT patients (Table 2). In our opinion increase in
the production of IFN-γ observed in Th1/Th17 lym-
phocytes in DM2 patients may reflect the beginning of
the skewing of Th1/Th17 differentiation axis to the
side of Th1 and may be typical to the progression of
the disease from the subclinical (IGT) to the clinically
manifested stage (DM2).
Reverse relationship between visceral adiposity index
(VAI) and number of FoxP3+ Treg-lymphocytes repre-
sent another important finding in our study. It had
been shown that both subcutaneous (SAT) and visceral
adipose tissue (VAT) compartments are characterized
by inflammation during obesity [43]. But VAT depot
possesses unique pathogenic properties and is even
termed an endocrine organ due to its ability to secrete
an impressive number of vasoactive substances includ-
ing adipokines [44]. BMI is a typical method used to as-
sess adiposity, but it has a number of shortcomings and
is not useful for evaluation of visceral adiposity [45].
VAI represents mathematical model aimed to evaluate
body fat distribution [26]. Even though this method is
not that precise as computer tomography or magnetic
resonance imaging for estimation of visceral fat volume,
it appeared to be more sensitive marker of cardiometa-
bolic risk than BMI or waist circumference alone [26,
44, 46]. In our study VAI values observed in patients
with DM2 tended to be higher than in other groups,
and were significantly higher compared to healthy vol-
unteers (Table 1). It was shown that repertoire of Tcells in adipose tissue vary depending on the degree of
obesity [21]. There is a hypothesis that peripherally
induced FoxP3+ Treg cells may be recruited in the
inflamed VAT, while thymic-derived natural Tregs are
represented in VAT during obesity insufficiently [47].
We may speculate that there are two possible ways to
explain the reverse correlation between FoxP3+ Treg
numbers and VAI observed in DM2 patients in our
study. It may reflect the universally diminished num-
bers of Treg lymphocytes typical for diseases accom-
panied by chronic inflammation [48–50]. In this case
systemic decrease of Treg cells may be associated with
the increase of adipose tissue volume and elevated local
production of inflammatory cytokines and adipokines.
Or the decline in peripheral blood numbers of Tregs
may be the consequence of FoxP3+ Tregs recruitment
to adipose tissue in order to control the local inflamma-
tion: the process which tends to proceed more actively
with the increase of visceral adiposity, estimated by ele-
vated VAI in our study [47].
Another clinical parameter closely related to immune
factors in DM2 patients was glomerular filtration rate.
It was inversely related to numbers of FoxP3+ Treg-
lymphocytes, numbers of Th17- and IL-23R+ cells in
intact PBMC culture [Fig. 4]. Baban B. et al. (2013)
revealed accumulation of IL-17 and IL-23 in kidneys of
db/db mice (animal model for type 2 diabetic nephrop-
athy) [15]. Zhang C. et al. (2014) demonstrated that
alteration of Th17/Treg ratio is typical for DM2
nephropathy [51]. The fact that patients recruited in
our study were characterized by normal renal function
indicates that disturbances of immune regulation dur-
ing DM2 are distinguishable even before the involve-
ment of kidneys into pathological process, but are still
interconnected with renal function in these patients.
Of interest remains relationships between immune pa-
rameters and kidney function in IGT patients, who had
the highest GFR-values, but no correlations were re-
vealed in this group. Possible explanation is a small
number of recruited patients with IGT.
We acknowledge the difference in the age of the
healthy volunteers and groups of patients as one of the
limitations in our study (Table 1). Incidence of insulin
resistance, arterial hypertension and conditions associ-
ated with them, as well as incidence of inflammatory
diseases, markedly increases with age, which significantly
limits number of individuals who may be considered as
“healthy” in general population aged 50 – 60 years old
[52, 53]. That is why we regarded group of hypertensive
patients without carbohydrate disturbances as a com-
parison group, and differences revealed between hyper-
tensive patients and hypertensive patients with DM2 or
IGT were considered to be due to the presence of
carbohydrate disturbances.
Kologrivova et al. Translational Medicine Communications  (2016) 1:2 Page 10 of 11Conclusions
Overall, our study underscores the involvement of im-
mune imbalance in the development of carbohydrate me-
tabolism perturbations and indicates possible directions of
the future application of our current knowledge to clinical
practice. Immune imbalance revealed in our study in
hypertensive patients with IGT included lowered ratio
Treg/Th17 and elevated expression of IL-23-receptor by
PBMC. Elevated numbers of Th17-lymphocytes in intact
PBMC culture and Th1-lymphocytes after PBMC activa-
tion, as well as reduced ratios Treg/Th17 and Treg/Th1
appeared to be the most important parameters in hyper-
tensive DM2 patients. Visceral adiposity index, concentra-
tions of total and LDL-cholesterol and glomerular
filtration rate were clinical factors most closely related to
immune imbalance in hypertensive patients with DM2.
Further prospective research is needed to elaborate the
possible strategy of the risk evaluation for the DM2 pa-
tients according to their current inflammatory status and
propose therapeutic approaches for its correction.
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